Sponsors
The bill trades shorter-term patient supply stability and regulatory predictability for outsourcing facilities against a longer window during which noncompliant practices can persist, raising patient safety and enforcement-delay risks.
Patients who rely on compounded sterile drugs will likely face fewer short-term supply disruptions because outsourcing facilities get a clear 180-day window to meet compliance conditions before losing certain authorizations.
Hospitals, health systems, and small-business outsourcing facilities gain regulatory predictability and reduced immediate risk of noncompliance penalties because they are given a defined 180-day compliance period.
Patients who receive compounded sterile drugs could face increased safety risks because potentially noncompliant practices may continue for up to 180 days before enforcement removes authorizations.
Hospitals, health systems, and outsourcing facilities may face weaker incentives to correct problems promptly because regulators' enforcement actions can be delayed during the 180-day compliance window.
Based on analysis of 2 sections of legislative text.
Introduced February 12, 2026 by Buddy Carter · Last progress February 12, 2026
Changes two timing phrases in the federal law for drug outsourcing facilities so that certain required actions or conditions must occur "within 180 calendar days" instead of "at the time." The change simply replaces ambiguous immediate-timing language with a clear 180-day window and does not create new programs, spending, or duties.